Key Highlights

  • AngioDynamics surged after reporting record fiscal year 2026 results, with Q4 revenue of $86.6 million beating estimates of $82 million.
  • Adjusted EPS of -$0.07 topped the -$0.09 consensus, while the Med Tech segment grew 16.7% year-over-year and now represents 47% of total revenue.
  • Canaccord Genuity raised its price target on ANGO from $16 to $20 while maintaining a Buy rating.
  • The company secured a new FDA IDE approval for a NanoKnife feasibility trial in BPH, expanding the platform's addressable market beyond oncology.

The most important number in AngioDynamics' (NASDAQ: ANGO) record fiscal year 2026 results isn't the revenue beat itself — it's the 47% figure, representing the share of total revenue now coming from the company's Med Tech segment. That number is the clearest evidence yet that a multi-year strategic transformation story is genuinely showing up in the actual business mix, rather than remaining an aspirational narrative management has been selling to investors.

The quarter's headline results were strong on their own terms: Q4 revenue of $86.6 million beat estimates of $82 million, and adjusted EPS of negative $0.07 topped the negative $0.09 consensus. Beating a negative EPS estimate is a specific kind of good news — the company is still not profitable on an adjusted basis, but it's losing less money than expected, which matters for the market's assessment of how close the business is to an eventual profitability inflection.

But the segment-level detail is where the real story lives. The Med Tech segment grew 16.7% year-over-year, a genuinely strong growth rate for a segment that now constitutes nearly half the company's total revenue base. Crossing the 47% threshold means Med Tech is no longer a growth story sitting alongside a larger, slower-growing legacy business — it's approaching parity as the company's primary revenue driver, a milestone that changes how investors should think about AngioDynamics' overall growth algebra going forward. A company where the fast-growing segment represents just 20% of revenue needs that segment to grow extremely quickly to move the overall growth needle; a company where it represents 47% sees company-wide growth increasingly tracking the Med Tech segment's own trajectory.

Canaccord Genuity's decision to raise its price target from $16 to $20 while maintaining a Buy rating reflects exactly this kind of recalibration — not a reaction to a single quarter's beat, but a broader reassessment of what the business is worth now that Med Tech's growing revenue contribution is becoming impossible to characterize as a side story.

Adding a specific, forward-looking growth catalyst to this quarter's results, AngioDynamics secured a new FDA Investigational Device Exemption (IDE) approval for a NanoKnife feasibility trial targeting benign prostatic hyperplasia (BPH). This is a meaningfully different kind of announcement than routine regulatory housekeeping — it represents an explicit expansion of NanoKnife's addressable market beyond its established oncology applications into a genuinely different, and in prevalence terms much larger, urological condition affecting a substantial portion of the aging male population.

NanoKnife's underlying technology, based on irreversible electroporation for tissue ablation, was originally developed and commercialized around treating certain cancers, and expanding its clinical application into BPH represents exactly the kind of platform-extension strategy that can meaningfully increase a medical device technology's total addressable market without requiring an entirely new product development effort from scratch. If the feasibility trial demonstrates a viable clinical use case in BPH, it would open a substantial new growth vector for the Med Tech segment that's already driving the majority of today's positive earnings reaction — reinforcing why this particular regulatory approval is being read alongside the earnings beat rather than treated as a standalone, minor announcement.